Is CDNA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Testing-volume growth, with revenue (ttm) at ~$458M. The bear case rests on reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a trailing revenue base near $458 million, although the recent Medicare coverage determination for allograft rejection testing has been read as favorable. Analysts covering it are spread from $46.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a trailing revenue base near $458 million, although the recent Medicare coverage determination for allograft rejection testing has been read as favorable. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $46.00, -28.1% from the $64.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Testing-volume growth. Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. The most optimistic analyst target on CDNA is $75.00, +17.2% from the $64.00 price. That figure is only reachable if this thesis works close to its best case.

Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a trailing revenue base near $458 million, although the recent Medicare coverage determination for allograft rejection testing has been read as favorable. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. Trailing GAAP net income of about $111 million is flattered by non-operating items, since operating margin is close to zero, so the core earnings turnaround is still early. Valuation has become a risk in its own right: after a 237% year-to-date gain the stock trades above the roughly $62 mean analyst target and at about 50 times forward earnings, and analysts expect 2027 revenue growth to slow to about 8%. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty. Walnut is not an investment adviser; this page describes the company and is not a recommendation. The most pessimistic published target is $46.00, -28.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Testing-volume growth) stalling in the reported numbers rather than in the narrative, the risk above (reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a trailing revenue base near $458 million, although the recent Medicare coverage determination for allograft rejection testing has been read as favorable) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CareDx provides diagnostics and services for the organ-transplant community. Its flagship tests, AlloSure and AlloMap, monitor kidney and heart transplant recipients for signs of rejection, and it also sells patient-management software and pharmacy services to transplant centers.

On a GAAP basis, yes: trailing twelve-month net income is about $111 million, and adjusted EPS beat estimates in Q1 2026 ($0.34 vs $0.13) and Q2 2026 ($0.37 vs $0.23). Most of the trailing net income came in Q2 2026 and exceeds operating profit, which is close to break-even on a trailing basis, so the core operating profitability trend is recent and not yet fully established.

Growth accelerated through 2026: Q1 revenue rose about 39% year over year and Q2 revenue about 52% to roughly $132 million. Management's early-2026 guidance was $447 million to $465 million of full-year revenue; analysts now expect about $495 million for 2026 and about $526 million for 2027, a slower 8% pace.